- Home
- / Helix BioPharma
Helix BioPharma
Stock Price
$0.9
2024-10-29
Market Capitalization
$44.1 M
2024-10-29
Helix BioPharma Summary
Company Summary
- Overview
- Helix BioPharma is a biopharmaceutical company developing therapies in the field of immuno-oncology, based on its technological platform DOS47. It is focused on the development of Topical Interferon Alpha-2b that employs Biphasix drug delivery technology and L-DOS47 for the treatment of metastatic non-small cell lung cancer (NSCLC).
- Type
- Public
- Status
- Active
- Founded
- 1995
- HQ
- Richmond Hill, CA | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
1 location detected
Richmond Hill, ON HQ
Canada
Leslie St
Helix BioPharma Financials
Summary Financials
- Net income (Q2, 2026)
- ($C694.0K)
- Cash (Q2, 2026)
- $C31.0K
- EBIT (Q2, 2026)
- ($C682.0K)
- Enterprise value
- $44.4M
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026